Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyHead and Neck OncologyNeuro-OncologyThoracic TumorsTumor, regardless of entityDiseaseBile Duct CarcinomaOvarian TumorPancreatic CancerTumor Biomarker DefinedSubgroupBRAF V600-MutationHER2+ICD10C24.-C24.0C24.1C24.8C24.9C25.-C56MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsCommon Bile Duct NeoplasmsNeoplasmsPancreatic NeoplasmsSequenceAntineoplastic therapySubstanceDabrafenibTrametinibTrastuzumab emtansineSubstanceDabrafenibTrametinibTrastuzumab emtansineSubstanceDabrafenibTrametinibTrastuzumab emtansineSubstanceDabrafenibTrametinibTrastuzumab emtansineNo. Substances12 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionGranisetronSubstanceBalanced Crystalloid SolutionGranisetronSubstanceBalanced Crystalloid SolutionGranisetronSubstanceBalanced Crystalloid SolutionGranisetronNo. Substances2Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaCardiotoxicityDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHepatotoxicityHyponatremiaIncrease Alkaline PhosphataseIncrease AminotransferasesNeuropathyNeutropeniaPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorJhaveri KLSalama AKSDiseaseLokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1OriginDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Protocols in Revision 2 protocols foundDabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)
